Literature DB >> 23822539

Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone.

Sewit Teckie1, Joachim Yahalom.   

Abstract

Primary intraocular lymphoma (PIOL) treatment in the absence of other involvement of the central nervous system is controversial. We evaluated the outcome of ocular radiation therapy (RT) alone in 18 patients with PIOL who had no imaging evidence of brain or meningeal involvement, treated from 1999 to 2011. Median age at diagnosis was 64 years (range 32-82). Median follow-up was 25 months. Eleven had bilateral ocular involvement. All received external-beam orbital RT to a median dose of 36 Gy. Twelve patients received ocular RT alone; seven remain relapse-free at a median follow-up of 30 months. Five experienced brain or eye recurrence and were effectively salvaged with chemotherapy ± RT. Six patients received chemotherapy before ocular RT; three relapsed and received salvage therapy. Overall survival (OS) at 2 years was 94%. Two-year freedom-from-relapse was not different between the groups. Ocular RT alone resulted in excellent ocular control of PIOL, and relapses were effectively salvaged.

Entities:  

Mesh:

Year:  2013        PMID: 23822539     DOI: 10.3109/10428194.2013.819576

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

Review 1.  [Special hematological diagnostics and therapy options for ocular lymphoma taking CNS involvement into account].

Authors:  A Korfel; U Schlegel; R Schroers
Journal:  Ophthalmologe       Date:  2015-03       Impact factor: 1.059

2.  Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma.

Authors:  Chan Yoon Cheah; Sarah Milgrom; Dai Chihara; Dan S Gombos; Chelsea C Pinnix; Bouthaina S Dabaja; Nathan H Fowler
Journal:  Neuro Oncol       Date:  2015-10-20       Impact factor: 12.300

3.  Case 01-2017 - Primary vitreoretinal lymphoma (PVRL): report of a case and update of literature from 1942 to 2016.

Authors:  Yujuan Wang; Dik S Cheung; Chi-Chao Chan
Journal:  Ann Eye Sci       Date:  2017-07-01

4.  Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma.

Authors:  Sarah A Milgrom; Chan Y Cheah; Chelsea C Pinnix; Grace L Smith; Bouthaina S Dabaja; Patricia Horace; Patricia Chevez-Barrios; Nathan H Fowler; Dan S Gombos
Journal:  Leuk Lymphoma       Date:  2016-04-13

Review 5.  A Glimpse into Uveitis in the Aging Eye: Pathophysiology, Clinical Presentation and Treatment Considerations.

Authors:  Elizabeth Akinsoji; Raquel Goldhardt; Anat Galor
Journal:  Drugs Aging       Date:  2018-05       Impact factor: 4.271

6.  Clinical Features, Diagnosis, Management and Prognosis of Primary Intraocular Lymphoma.

Authors:  Xin-Yu Zhao; Tian-Tian Cheng; Li-Hui Meng; Wen-Fei Zhang; You-Xin Chen
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

7.  Diagnosing Vitreoretinal Lymphomas-An Analysis of the Sensitivity of Existing Tools.

Authors:  Anahita Sehgal; Jose S Pulido; Arman Mashayekhi; Tatyana Milman; Gabor Gy Deák
Journal:  Cancers (Basel)       Date:  2022-01-25       Impact factor: 6.639

Review 8.  Central Nervous System Progression in Primary Vitreoretinal Lymphoma with Bilateral and Unilateral Involvement: A Systematic Review and Meta-Analysis.

Authors:  Josephus L M van Rooij; Klaudia A Tokarska; Ninette H Ten Dam-van Loon; Peter H Wessels; Tatjana Seute; Monique C Minnema; Tom J Snijders
Journal:  Cancers (Basel)       Date:  2022-06-16       Impact factor: 6.575

9.  Insights from a Case of Vitreoretinal Lymphoma.

Authors:  Bertil E Damato; Gregory J Bever; Armin R Afshar; James L Rubenstein
Journal:  Ocul Oncol Pathol       Date:  2018-04-17

10.  Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study.

Authors:  Yan Zhang; Xiao Zhang; Dongmei Zou; Jingjing Yin; Li Zhang; Xuan Wang; Congwei Jia; Wei Wang; Danqing Zhao; Daobin Zhou; Wei Zhang; Meifen Zhang
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.